** Brokerage UBS starts coverage on TASER maker Axon Enterprise AXON.O with "neutral" rating and $820 PT
** PT implies a 9.94% upside to the stock's last close
** UBS expects Axon’s revenue to grow by 21% annually over the next five years, fueled by expansion in U.S. and international public safety markets, increased enterprise adoption, and the development of new technologies such as drones
** Brokerage says Axon’s strong growth prospects are already factored into the current share price, so risk and reward are balanced
** UBS notes that while Axon's international and enterprise segments are currently smaller contributors, international revenue grew 37% last year, and could become the company’s largest segment in the future, though both remain in the early stages of growth
** As of last close, AXON stock up 25.5% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.